share_log

Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the prima

Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the prima

禮來公司和Incell公司宣佈了巴利替尼在住院新冠肺炎患者中的3期COV屏障研究的結果，該試驗在初始階段沒有統計學意義
Benzinga Real-time News ·  2021/04/08 18:46

Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the primary endpoint'

禮來公司和Incell公司公佈了巴利替尼在住院新冠肺炎患者中的3期COV屏障研究結果，該公司的報告稱，該試驗沒有達到主要終點的統計學意義。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論